News Quantified

VIR – vir biotechnology, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Vir Biotechnology (VIR) had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.

Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus [Yahoo! Finance]

Vir Biotechnology to Participate in Upcoming Investor Conferences

Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.

Vir Biotechnology Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]

-12.9%

BEAT

-5.2%

MISS

-14.4%

MISS

-8.1%

MISS

Leerink Partners

Form 8-K Vir Biotechnology, Inc. For: Mar 04

Form SCHEDULE 13D/A Vir Biotechnology, Inc. Filed by: ARCH Venture Fund IX, L.P.

Form 4 Vir Biotechnology, Inc. For: Mar 02 Filed by: SATO VICKI L

Form 144 Vir Biotechnology, Inc. Filed by: SATO VICKI L

Form 8-K Vir Biotechnology, Inc. For: Feb 26

Top News Gainers

2/25 CDC Issues Warnings on Virus; Markets Take Hit: Virus Update [Yahoo! Finance News] 61.4%

2/27 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Robert W. Baird from a "neutral" rating to an "underperform" rating. 58.5%

3/13 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. 21.3%

4/6 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions 21.1%

3/13 Eli Lilly CEO aims to start testing coronavirus cure 'this summer' [CNBC] 14.1%

2/25 CDC Tells Americans to Start Readying for Outbreak: Virus Update [Yahoo! Finance News] 12.9%

1/15 Vir Biotechnology (VIR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] 12.5%

3/10 Vir Biotechnology to Present at Barclays Global Healthcare Conference 10.0%

3/26 Q4/2019 12/31/2019 EPS -0.710 ZacksConsensus -0.470 ActVsEst (0.240) - Miss 7.2%

10/18 Form 4 Vir Biotechnology, Inc. For: Oct 16 Filed by: Fullerton Management Pte Ltd 5.5%

Top News Decliners

2/28 Trending Ticker: VIR Surges as Coronavirus fears persist [Yahoo! Finance News] -35.9%

3/9 Form 8-K Vir Biotechnology, Inc. For: Mar 03 -22.1%

4/7 Biotechs Working Closely & Feverishly With CDC for COVID-19 Vaccine Development -14.4%

3/6 Why Was Vir Biotechnology Up 74% in February? [The Motley Fool] -14.2%

10/10 Form 3 Vir Biotechnology, Inc. For: Oct 10 Filed by: Platinum International Investment Holding RSC Ltd -13.2%

4/8 Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218 -11.2%

3/19 Vir Biotechnology (NYSE: VIR) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. -10.8%

2/12 Form 8-K Vir Biotechnology, Inc. For: Feb 12 -10.2%

3/25 Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19 -8.5%

4/6 GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln [Reuters] -8.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day